Prevail Therapeutics Inc. Common Stock
PRVL
PRVL was delisted on the 21st of January, 2021.
58 hedge funds and large institutions have $339M invested in Prevail Therapeutics Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 2 closing their positions.
600% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 2
150% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 10
26% more funds holding
Funds holding: 46 → 58 (+12)
21% less capital invested
Capital invested by funds: $427M → $339M (-$87.9M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.72M |
| 2 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$4.57M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$4M |
| 4 |
AG
Artal Group
Luxembourg
|
+$3.18M |
| 5 |
QF
QVT Financial
New York
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$6.3M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.14M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$3.58M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$1.96M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.33M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SO
51
STRS Ohio
Columbus,
Ohio
| $23K | – | – | – |
|
|
TRCT
52
Tower Research Capital (TRC)
New York
| $16K | -$45.4K | -2,853 | -68% |
|
|
AIP
53
Ameritas Investment Partners
Lincoln,
Nebraska
| $15K | +$9.63K | +605 | +98% |
|
54
Royal Bank of Canada
Toronto,
Ontario, Canada
| $12K | -$8.19K | -515 | -35% |
|
55
US Bancorp
Minneapolis,
Minnesota
| $7K | +$9.55K | +600 | New |
|
56
Daiwa Securities Group
Tokyo,
Japan
| $2K | – | – | – |
|
|
TPWA
57
TRUE Private Wealth Advisors
Salem,
Oregon
| $2K | +$3.18K | +200 | New |
|
|
FAM
58
Fred Alger Management
New York
| – | -$47K | -3,000 | Closed |
|
59
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$15K | -936 | Closed |
|
PRVL Hedge Fund Activity: Q1 2020 in Review
58 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q1 2020, worth a combined $339M — down 21% from $427M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PRVL positions and 2 closed out — a net gain of 12 holders — while 25 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $6.72M. The largest seller was Omega Fund Management, cutting an estimated $6.3M.
- 58 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q1 2020, up from 46 in Q4 2019.
- Funds reported $339M of Prevail Therapeutics Inc. Common Stock stock for Q1 2020, down 21% quarter-over-quarter.
- 14 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q1 2020 and 2 closed out, a net change of +12 holders.
- The largest Prevail Therapeutics Inc. Common Stock buyer in Q1 2020 was BlackRock, an estimated $6.72M added.
- The largest Prevail Therapeutics Inc. Common Stock seller in Q1 2020 was Omega Fund Management, an estimated $6.3M sold.
Based on aggregated 13F filings for Q1 2020.